Medical Devices New Zealand

New Zealand Tuberculosis Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

New Zealand Tuberculosis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $26.7 Mn Placeholder estimate
Estimate 2025 $28.4 Mn 1.1% of the global market
Projected 2034 $49.7 Mn 74.8% Adds $21.2 Mn over 9 forecast years
CAGR 2025–2034 6.4% Faster than 16% of 160 Medical Devices markets here
Key players 5
  • New Zealand is 1.1% of the global market.
  • In APAC, the largest is China at $232.9 Mn.
  • Fastest growing: India at 9.1% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$21.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Tuberculosis Diagnostics Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $26.7 Mn — —
2025 (base) $28.4 Mn +$1.7 Mn —
2026 (forecast) $30.2 Mn +$1.8 Mn +6.4%
2027 (forecast) $32.2 Mn +$1.9 Mn +13.2%
2028 (forecast) $34.2 Mn +$2.1 Mn +20.5%
2029 (forecast) $36.4 Mn +$2.2 Mn +28.2%
2030 (forecast) $38.7 Mn +$2.3 Mn +36.4%
2031 (forecast) $41.2 Mn +$2.5 Mn +45.1%
2032 (forecast) $43.9 Mn +$2.6 Mn +54.4%
2033 (forecast) $46.7 Mn +$2.8 Mn +64.3%
2034 (forecast) $49.7 Mn +$3.0 Mn +74.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand Tuberculosis Diagnostics Market Analysis at a glance
Market size, 2025$28.4 Mn placeholder estimate
Forecast, 2034$49.7 Mn placeholder estimate
Growth (CAGR), 2025–20346.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, setting and end user (see all)
Key playersCepheid, Qiagen N.V., Molbio Diagnostics, Qure.ai, Revvity (see all)
Regulator in New ZealandMedsafe (WAND)Source: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand Tuberculosis Diagnostics Market Analysis Executive Summary

Tuberculosis diagnostics find TB infection and disease using skin tests, blood tests, molecular tests and chest X-ray reading.

Key segments of the tuberculosis Diagnostics market include test (Molecular Tests, Interferon Gamma Release Assays and Skin Tests) and setting (Hospitals, TB Programs and Point of Care).

Bar chart: New Zealand Tuberculosis Diagnostics market size, 2024–2034, placeholder estimates. $26.7 Mn in 2024, $28.4 Mn in 2025 and $49.7 Mn in 2034, 6.4% CAGR.
New Zealand Tuberculosis Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand Tuberculosis Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the tuberculosis Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the tuberculosis Diagnostics market.

Competitive Landscape for Tuberculosis Diagnostics Market in New Zealand

The tuberculosis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Tuberculosis Diagnostics Market in New Zealand

Tuberculosis Diagnostics in New Zealand: rules, payment and health figures

Medical devices do not need approval before sale, but suppliers must notify them to the WAND database run by Medsafe.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2] Tuberculosis new cases: 8 per 100,000 people in 2024, the latest World Bank figure for New Zealand.⁠[3]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

[3] World Bank Open Data, Tuberculosis new cases (per 100,000 people). Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how tuberculosis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Tuberculosis Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Tuberculosis Diagnostics in context

New Zealand compared

  • Tuberculosis new cases: 8 per 100,000 people (2024). World: 131 per 100,000 people (2024). 17th highest of the 18 countries we cover in APAC.[1]
  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 17 countries we cover in APAC.[2]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 17 countries we cover in APAC.[3]

[1] World Bank Open Data, Tuberculosis new cases (per 100,000 people). Retrieved 21 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Tuberculosis Diagnostics market in New Zealand?
Placeholder estimate: about $28.4 Mn in 2025, rising to about $49.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Tuberculosis Diagnostics market in New Zealand growing?
Placeholder estimate: about 6.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Tuberculosis Diagnostics market report cover?
The report splits the market by test (Molecular Tests, Interferon Gamma Release Assays, Skin Tests, Sputum Smear and more), setting (Hospitals, TB Programs, Point of Care) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Tuberculosis Diagnostics market?
Key players include Cepheid, Qiagen N.V., Molbio Diagnostics, Qure.ai and Revvity.
What is driving the Tuberculosis Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Who regulates Tuberculosis Diagnostics in New Zealand?
Medical devices do not need approval before sale, but suppliers must notify them to the WAND database run by Medsafe. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
What does World Bank report for New Zealand?
Tuberculosis new cases: 8 per 100,000 people in 2024, the latest World Bank figure. Source: World Bank Open Data, Tuberculosis new cases (per 100,000 people). Retrieved 21 Nov 2026.
How many people in New Zealand are 65 or older?
17.6% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 21 Nov 2026.
How much research is published on Tuberculosis Diagnostics?
PubMed lists 80 papers on Tuberculosis Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in New Zealand

See all

Related on diagnostics and lab testing and tuberculosis

See the topic